Zobrazeno 1 - 10
of 538
pro vyhledávání: '"E Atalar"'
Autor:
A, Erden, O, Karakas, B, Armagan, S C, Guven, B, Ozdemir, E, Atalar, H, Apaydin, E, Usul, I, Ates, A, Omma, O, Kucuksahin
Publikováno v:
Bratislava Medical Journal. 123:120-124
Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS).A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR‑positive patients, cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b47a1f45334a93c87de5360dd781619
https://doi.org/10.4149/bll_2022_018
https://doi.org/10.4149/bll_2022_018
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. Yetkin, Y.Z. Şener, A.H. Ateş, M.L. Şahiner, E.B. Kaya, E. Atalar, K. Aytemir, L. Tokgözoğlu
Publikováno v:
Atherosclerosis. 355:266-267
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8a6c024cf20e1f4e6d6218a8895b5a
https://doi.org/10.1016/j.atherosclerosis.2022.06.1003
https://doi.org/10.1016/j.atherosclerosis.2022.06.1003
Autor:
Y.Z. Şener, S. Ardali, A.H. Ateş, M.L. Şahiner, E.B. Kaya, T. Hazirolan, E. Atalar, N. Özer, K. Aytemir, L. Tokgözoğlu
Publikováno v:
Atherosclerosis. 355:265-266
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::829cb27b244dda739f604b3a798627a7
https://doi.org/10.1016/j.atherosclerosis.2022.06.1001
https://doi.org/10.1016/j.atherosclerosis.2022.06.1001
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Y.Z. Şener, S. Ardali, U.N. Karakulak, A.H. Ateş, M.L. Şahiner, E.B. Kaya, T. Hazirolan, E. Atalar, N. Özer, K. Aytemir, L. Tokgözoğlu
Publikováno v:
Atherosclerosis. 355:265
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45ec1f248f233f8a0418f10b1c2ac91e
https://doi.org/10.1016/j.atherosclerosis.2022.06.1000
https://doi.org/10.1016/j.atherosclerosis.2022.06.1000
Autor:
B. Armagan, E. Atalar, B. Özdemir, Ö. Karakaş, E. Kayacan Erdogan, S. C. Güven, I. Dogan, O. Küçükşahin, A. Erden
Publikováno v:
Annals of the Rheumatic Diseases. 81:1702.2-1703
BackgroundRheumatological disease flares may be seen after many infections. However, our knowledge for the post-COVID axial spondyloarthritis (SpA) flares and its related factors is limited.ObjectivesWe aimed to evaluate disease activity and factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60d95447612c7967c5e6bb877456fccb
https://doi.org/10.1136/annrheumdis-2022-eular.4769
https://doi.org/10.1136/annrheumdis-2022-eular.4769
Autor:
B. Armagan, E. Atalar, S. C. Güven, B. Özdemir, H. E. Konak, P. Akyüz Dağli, A. Erden, K. Gok, Y. Maraş, I. Dogan, O. Küçükşahin, S. Erten, A. Omma
Publikováno v:
Annals of the Rheumatic Diseases. 81:1688.2-1688
BackgroundCompared to biologic-agents, little is known about effects of sulfasalazine used for axial spondyloarthritis(AxSpA) on COVID-19 outcomes.ObjectivesSo, we aimed to understand the impact of sulfasalazine on COVID-19 in AxSpA patients.MethodsT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aec84836b58db670a3d8e071ef996d4
https://doi.org/10.1136/annrheumdis-2022-eular.3685
https://doi.org/10.1136/annrheumdis-2022-eular.3685
Publikováno v:
Annals of the Rheumatic Diseases. 81:960.1-960
BackgroundAnti-phospholipid syndrome (APS) is an autoimmune disorder characterized by presence of anti-phospholipid antibodies (aPL) comprising lupus anticoagulant, anti-β2-glycoprotein I and/or anti-cardiolipin antibodies together with recurrent th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a31a629839074c99eeee8f91fa0784a
https://doi.org/10.1136/annrheumdis-2022-eular.3542
https://doi.org/10.1136/annrheumdis-2022-eular.3542
Autor:
S. C. Güven, Ö. Karakaş, E. Atalar, H. E. Konak, P. Akyüz Dağli, E. Kayacan Erdogan, B. Armagan, K. Gok, I. Dogan, Y. Maraş, A. Erden, S. Erten, O. Küçükşahin, A. Omma
Publikováno v:
Annals of the Rheumatic Diseases. 81:973.3-974
BackgroundTo prevent COVID-19 disease SARS-CoV 2 vaccines put into use worldwide with emergency use authorizations despite ongoing safety concerns. Since pyrin mediated inflammasome response is dysregulated in FMF, exposure to SARS-CoV 2 proteins via
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a9956f3bd62373ef818dbb9d9bf6a29
https://doi.org/10.1136/annrheumdis-2022-eular.4920
https://doi.org/10.1136/annrheumdis-2022-eular.4920